A federal judge in the Eastern District of New York has granted final approval of a settlement of a class action lawsuit brought by consumers and other end-payors concerning the price of Restasis, a prescription drug used to treat dry-eye problems.
Allergan will pay $30 million to settle the end-payors’ claims in the multidistrict antitrust litigation asserting an anticompetitive scheme to preserve its Restasis patent monopoly.
In an order issued on August 2, 2022, U.S. District Judge Nina Gershon found in part that Girard Sharp and its co-lead counsel “are extremely experienced in litigating pharmaceutical antitrust cases on behalf of end-payors. During their court appearances before me and in their written submissions, they were thorough, diligent, and professional as they prosecuted this complex, discovery-intensive, and expert-dependent action. In addition to opposing, with nearly complete success, two motions to dismiss, counsel litigated, intensively and successfully, a complicated class certification motion, which involved not only extensive briefing but a two-day evidentiary hearing. Counsel also completed lengthy briefing on summary judgment motions and 11 Daubert motions.”
Girard Sharp attorneys Dena Sharp, Scott Grzenczyk, and Tom Watts prosecuted the end-payor claims in the Restasis case.
If you bought or provided reimbursement for Restasis between May 1, 2015 and July 31, 2021, you may be eligible for a payment. For instructions on how to file a claim, visit https://www.restasislitigation.com/.
Click here to read more about Girard Sharp’s track record of successfully helping clients achieve precedent-setting outcomes against some of the nation’s biggest pharmaceutical companies.
